Arrowhead Pharmaceuticals’ (ARWR) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a report released on Thursday,Benzinga reports. Chardan Capital currently has a $60.00 price target on the biotechnology company’s stock.

Other equities analysts also recently issued research reports about the stock. Royal Bank of Canada reissued an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Wednesday, November 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 9th. HC Wainwright raised their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Finally, Piper Sandler lowered their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $42.70.

Arrowhead Pharmaceuticals Trading Down 1.3 %

NASDAQ ARWR opened at $21.85 on Thursday. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. The company has a 50-day simple moving average of $20.98 and a 200-day simple moving average of $23.14. Arrowhead Pharmaceuticals has a one year low of $17.05 and a one year high of $39.83. The firm has a market capitalization of $2.72 billion, a PE ratio of -4.35 and a beta of 0.91.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ARWR. SG Americas Securities LLC grew its holdings in Arrowhead Pharmaceuticals by 27.4% in the 2nd quarter. SG Americas Securities LLC now owns 9,369 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 2,014 shares during the last quarter. Fifth Third Bancorp grew its stake in shares of Arrowhead Pharmaceuticals by 42.5% in the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 354 shares during the last quarter. EFG Asset Management North America Corp. increased its position in Arrowhead Pharmaceuticals by 86.8% during the second quarter. EFG Asset Management North America Corp. now owns 51,828 shares of the biotechnology company’s stock worth $1,346,000 after acquiring an additional 24,083 shares during the period. Bank of New York Mellon Corp raised its stake in Arrowhead Pharmaceuticals by 2.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,085,069 shares of the biotechnology company’s stock valued at $28,201,000 after purchasing an additional 30,086 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Arrowhead Pharmaceuticals by 20.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,739 shares of the biotechnology company’s stock valued at $747,000 after purchasing an additional 4,927 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.